Biological
mRNA-1345 respiratory syncytial virus vaccine clinical trials
Also written mRNA-1345.
- studies test it
- 11
- open now
- 0
- in phase 3
- 5
- first study started
- 2020
How studies write it
Studies that test it under each name
Development codes
Studies by the year they started
11 studies that test it; most in 2023 (5)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 3 |
| 2023 | 5 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 4
- Phase 2
- 3
- Phase 3
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 11 · Other 0
Often tested with
Tested in the same studies.
mRNA-1010 influenza vaccine (2) · mRNA-1273.214 COVID-19 vaccine (2) · MRNA-1365 (1) · 2019-nCoV Vaccine mRNA-1273 (1) · mRNA-1647 cytomegalovirus vaccine (1) · Influenza Vaccines (1) · MRNA-1045 (1) · MRNA-1230 (1)
Studies
Open first, then newest update. How each study uses mRNA-1345 respiratory syncytial virus vaccine is read from its arms, and is right about nine times in ten.
Testing it · 11
- A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥60 Years of AgeCompletedPhase 2/3ModernaTX, Inc.NCT05127434Written as mRNA-1345
- A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk AdultsCompletedPhase 3ModernaTX, Inc.NCT06067230Written as mRNA-1345
- A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial VirusCompletedPhase 2ModernaTX, Inc.NCT06097299Written as mRNA-1345
- A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 MonthsActive, not recruitingPhase 1ModernaTX, Inc.NCT05743881Written as mRNA-1345
- A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus in Pregnant Women and in Infants Born to Vaccinated MothersCompletedPhase 2ModernaTX, Inc.NCT06143046Written as mRNA-1345
- A Study of mRNA-1345 Following a Primary Dose of a Licensed Protein Subunit Respiratory Syncytial Virus (RSV) Vaccine in Adult Participants ≥60 Years of AgeCompletedPhase 3ModernaTX, Inc.NCT07117487Written as mRNA-1345
- A Study of Modified mRNA Vaccines in Healthy AdultsCompletedPhase 1ModernaTX, Inc.NCT05397223Written as mRNA-1345
- A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥50 Years of AgeCompletedPhase 3ModernaTX, Inc.NCT05330975Written as mRNA-1345
- A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ≥65 Years of AgeCompletedPhase 3ModernaTX, Inc.NCT06060457Written as mRNA-1345
- A Dose Escalation Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1345 in Healthy Adults and in Children Who Are Respiratory Syncytial Virus (RSV)-SeropositiveCompletedPhase 1ModernaTX, Inc.NCT04528719Written as mRNA-1345
- A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1045 (Influenza and Respiratory Syncytial Virus [RSV]) or mRNA-1230 (Influenza, RSV, and Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2]) Vaccine in Adults 50 to 75 Years OldCompletedPhase 1ModernaTX, Inc.NCT05585632Written as mRNA-1345
Given in every arm · 1 — mRNA-1345 respiratory syncytial virus vaccine is usual care beside what is tested
As the comparator · 1 — what is tested is compared with mRNA-1345 respiratory syncytial virus vaccine
Codes
What other systems call mRNA-1345 respiratory syncytial virus vaccine · ClinicalTrials.gg INT001888
- MeSH (NLM) C000722749mRNA-1345 respiratory syncytial virus vaccineOne source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000722749 | mRNA-1345 respiratory syncytial virus vaccine | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.